YN360459 Lansoprazole D4 934294-22-1

Lansoprazole D4 (AG-1749 D4) is a deuterium labeled Lansoprazole. Lansoprazole is aproton pumpinhibitor which prevents the stomach from producing acid.

YN450152 ROCK-IN-1 934387-35-6

ROCK-IN-1 is a potent inhibitor ofROCK, with an IC50 of 1.2nM for ROCK2.

YN330013 Visomitin 934826-68-3

Visomitin (SKQ1) is a novel mitochondrial-targeted antioxidant that holds promise in the treatment of inflammation associated with ocular surface diseases such as dry eye disease (DED) and corneal wounds. SkQ1 shows a TC50 of ...

YN320587 PF-03654764 935840-35-0

PF-03654764 is an orally active, selective histamineH3receptor antagonist with Ki values of 1.2nM and 7.9nM for human H3 and rat H3in whole cell assay, respectively. The combination of PF-03654764 and Fexofenadine (HY-B0...

YN321042 Fiboflapon 936350-00-4

Fiboflapon (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (FLAP) inhibitor with a potency of 2.9nM in FLAP binding, an IC50 of 76nM for inhibition ofLTB4in human blood.

YN360414 Lumacaftor 936727-05-8

VX-809 (Lumacaftor) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM in fisher rat thyroid cells. Phase 3.

YN370153 Cyclo(his-pro) TFA 936749-56-3

Cyclo(his-pro) TFA (Cyclo(histidyl-proline) TFA) is an orally active cyclic dipeptide structurally related to tyreotropin-releasing hormone. Cyclo(his-pro) TFA could inhibitNF-κBnuclear accumulation. Cyclo(his-pro) TFA c...

YN371109 FIPI 939055-18-2

FIPI (5-Fluoro-2-indolyl deschlorohalopemide), a derivative of halopemide, is a potent and selective inhibitor of phospholipase D with IC50 of 25 nM and 20 nM for PLD1 and PLD2, respectively.

YN251860 IDR-1 940291-10-1

IDR-1 is an antimicrobial peptide that is active againstGram-positive and Gram-negative bacteria. IDR-1 counters infection by selective modulation of innate immunity without obvious toxicities. IDR-1 has anti-inflammatory and a...

YN330121 H-151 941987-60-6

H-151 is a highly potent and covalent antagonist of STING that has noteworthy inhibitory activity both in human cells and in vivo.

YN330420 Meloxicam D4 942047-63-4

Meloxicam D4 is deuterium labeled Meloxicam. Meloxicam is a non-steroidal antiinflammatory agent, inhibits COX activity, with IC50s of 0.49 µM and 36.6 µM for COX-2 and COX-1, respectively.

YN330418 Piroxicam D3 942047-64-5

Piroxicam D3 (CP-16171 D3) is deuterium labeled Piroxicam. Piroxicam is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25μM for human monocyte COX-1 and COX-2, respectively.

YN483861 VKGILS-NH2 942413-05-0

VKGILS-NH2 is a reversed amino acid sequence control peptide for SLIGKV-NH2 (protease-activated receptor 2 (PAR2) agonist). VKGILS-NH2 has no effect on DNA synthesis in cells.

YN360256 AZD7325 942437-37-8

AZD7325 is a potent and orally active partial selective PAM ofGABAAα2 and Aα3 receptor(Ki=0.3 and 1.3nM, respectively), and has less antagonistic efficacy at the Aα1  and Aα5 receptor subtypes . AZD7325 is ...

YN300082 Vedolizumab 943609-66-3

Vedolizumab is a humanized monoclonal antibody that targets the α4β7integrinfor the treatment of ulcerative colitis and Crohn's disease.

YN481611 Acebilustat 943764-99-6

Acebilustat (CTX-4430) is a leukotriene A4 hydrolase inhibitor, used for an oral antiinflammatory drug.

YN321871 PG106 944111-22-2

PG106 is a potent and selectivehuman melanocortin 3 (hMC3) receptorantagonist (IC50=210nM) and has noactivity at hMC4 receptors (EC50=9900nM) and  hMC5 receptor.

YN340218 Peficitinib 944118-01-8

Peficitinib (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.

YN440106 Lck inhibitor 2 944795-06-6

Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively ...

YN340101 Decernotinib 944842-54-0

Decernotinib (VX-509) is a potent and selective JAK3 inhibitor with Ki of 2.5 nM, >4-fold selectivity over JAK1, JAK2, and TYK2, respectively. Phase 2/3.